Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 334

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

Open access
Schiller, John T., Castellsagué, Xavier, Villa, Luisa L., Hildesheim, Allan·2008·Vaccine

Abstract

This review focuses on recent publications of clinical trials of two prophylactic Human Papillomavirus (HPV) vaccines: Gardasil® (Merck & Co., Whitehouse Station, NJ USA), a quadrivalent vaccine containing L1 virus-like particles (VLPs) of types −6, 11, 16, and 18, and Cervarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent vaccine containing VLPs of types −16 and 18. In efficacy trials involving young women, both vaccines produced outstanding efficacy against primary and secondary endpoints associated with the vaccine type HPVs and were highly and consistently immunogenic. Both had excellent safety records and, as expected, the most frequent vaccine-related adverse was moderate injection site sequelae. No evidence of waning protection was observed after four years for endpoints examined ranging from incident infection to cervical intraepithelial neoplasia grade 3 associated with the vaccine type HPVs. Gardasil® was also highly efficacious at preventing vaginal/vulvar lesions and genital warts. However, neither vaccine demonstrated therapeutic efficacy against prevalent infections or lesions, regardless of the associated HPV type. Cervarix® has shown limited cross-protection against infection with specific closely related types while preliminary results of limited cross-protection have been presented for Gardasil®. As expected, more limited efficacy was noted for both vaccines when women with prevalent infection were included or end points associated with any HPV type were evaluated. Immunological bridging trials involving adolescent girls and boys were also recently published. For both vaccines, serum VLP antibody levels in girls were non-inferior to those generated in young women and antibody response to Gardasil® was also non-inferior in boys. The results of these studies have led to the approval of Gardasil® and Cervarix® by national regulatory agencies in a number of countries.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2008.06.002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 334

Metadata

Authors
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A.
Venue
Vaccine
Publisher
Elsevier BV
Published
2008-08
Volume
26
Pages
K53-K61
ISSN
0264-410X (ISSN-L)
OpenAlex
W2029997802
Cited by
334
References
1
FWCI
30.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. https://app.cochat.ai/papers/10.1016/j.vaccine.2008.06.002
The paper
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008). An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. https://doi.org/10.1016/j.vaccine.2008.06.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.